AlphaQuest LLC Invests $52,000 in TransMedics Group, Inc. (NASDAQ:TMDX)

AlphaQuest LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, HoldingsChannel.com reports. The fund bought 828 shares of the company’s stock, valued at approximately $52,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hager Investment Management Services LLC purchased a new position in TransMedics Group during the fourth quarter valued at approximately $33,000. Sachetta LLC purchased a new position in TransMedics Group during the fourth quarter valued at approximately $40,000. Quarry LP grew its position in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares in the last quarter. National Bank of Canada FI grew its position in TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares in the last quarter. Finally, Arcadia Investment Management Corp MI purchased a new position in TransMedics Group during the fourth quarter valued at approximately $72,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $68.84 on Friday. The firm has a fifty day simple moving average of $68.12 and a 200-day simple moving average of $91.74. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of 73.23 and a beta of 2.12.

Wall Street Analyst Weigh In

A number of brokerages recently commented on TMDX. Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Oppenheimer reissued an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Finally, Piper Sandler decreased their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.